Cartesian Capital Partners is in discussions with Ignis Asset Management to move the distribution of its fund range from Ignis to National Wealth Service, Money Marketing understands. Ignis currently ...
On Friday, Mizuho Securities has resumed coverage on Cartesian Therapeutics shares, trading on NASDAQ:RNAC, assigning a Buy rating with a price target of $40.00. The coverage relaunch comes after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback